GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Debt-to-Equity

Abbott Laboratories (Abbott Laboratories) Debt-to-Equity : 0.41 (As of Dec. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Abbott Laboratories Debt-to-Equity?

Abbott Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,080 Mil. Abbott Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14,548 Mil. Abbott Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $38,603 Mil. Abbott Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Abbott Laboratories's Debt-to-Equity or its related term are showing as below:

ABT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.36   Med: 0.57   Max: 1.07
Current: 0.41

During the past 13 years, the highest Debt-to-Equity Ratio of Abbott Laboratories was 1.07. The lowest was 0.36. And the median was 0.57.

ABT's Debt-to-Equity is ranked worse than
67.28% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs ABT: 0.41

Abbott Laboratories Debt-to-Equity Historical Data

The historical data trend for Abbott Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Debt-to-Equity Chart

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.60 0.53 0.48 0.41

Abbott Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.45 0.41 0.41 N/A

Competitive Comparison of Abbott Laboratories's Debt-to-Equity

For the Medical Devices subindustry, Abbott Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Debt-to-Equity falls into.



Abbott Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Abbott Laboratories's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Abbott Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbott Laboratories  (NYSE:ABT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Abbott Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q4 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024